Actavis’ newly appointed senior management team effective after Allergan acquisition

Actavis announced that the company’s newly appointed management team will become effective immediately after the anticipated successful close of the Allergan acquisition in the second quarter of 2015, according to a press release.

Brent Saunders will continue to serve as CEO, president and member of the board of directors, and Paul Bisaro will continue as executive chairman of the board of directors, the release said.

With the acquisition, global brand sales and marketing will be structured into three organizations: International Brands, Branded Pharma and Allergan Medical.

The newly appointed senior management team includes Paul Navarre as executive vice president of Actavis and president of International Brands; William Meury as executive vice president of Actavis and president of Branded Pharma; Philippe Schaison as executive vice president of Actavis and president of Allergan Medical; Robert Stewart as executive vice president of Actavis and president of generics and global operations; Maria Teresa Hilado as executive vice president and chief financial officer; Robert Bailey as executive vice president and chief legal officer and corporate secretary; Karen Ling as executive vice president and chief human resources officer; Charlie Mayr as executive vice president and chief communications officer; Sigurd Kirk as executive vice president and corporate business development; and Jonathan Kellerman as executive vice president and global chief compliance officer.

C. David Nicholson, PhD, will be executive vice president of branded research and development. Alex Kelly and Sanjiv Patel will share the responsibility for pre-integration planning.

“The management structure we are announcing today will ensure that we capitalize on the value of Allergan’s world-renowned businesses and the proven track record of the leaders of its powerful and critically important franchises,” Saunders said in the release.